KIT and non-small cell lung carcinoma: Only sorafenib and sunitinib, which are multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR)-2 (class IV RTK), PDGFR-β, c-KIT, and FLT3, have shown significant antitumor activity and anti-angiogenesis in the preclinical models of various tumor types, including NSCLC [7,8].